An innovative minimally invasive, active medical device platform for remote neurological monitoring of brain cancer patients to aid treatment/care

点击翻译按钮获取中文摘要

Opto is a UK-based medical device SME with a core project team of Dr Ben Woodington (CEO), Dr Elise Jenkins (Project Lead/CTO) and Jose Lepe (Product Lead).Electrical monitoring devices are crucial for managing neurological diseases such as brain cancer, epilepsy, and Parkinson's disease. These conditions affect around 105K people annually in the UK alone. Unfortunately, current technologies have made little headway with remote treatment, as they are invasive, uncomfortable and require hospital monitoring, which limits their use to short periods and restricts at-home use. This is problematic for two reasons. First, managing these diseases costs the NHS over £2B per year, and patients lose around £3B in productivity due to ongoing assessments. Secondly, infrequent, inconsistent 'snapshot' assessments of neurological health do not provide the full benefits of the technology, which could help guide treatment, inform disease progression and provide advance warning to patients.People who do not live near major hospitals with advanced facilities (~20 % of UK residents) and lower-income groups who lack the means to travel for treatment regularly are disproportionately affected by this.Opto has developed a minimally invasive, active medical technology platform that enables remote neurological monitoring of brain cancer patients to aid disease treatment and management. This innovation will improve the quality of life of patients suffering from neurological diseases, starting with brain cancer.